Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy

por Miller, Bryan W, Morton, Jennifer P, Pinese, Mark, Saturno, Grazia, Jamieson, Nigel B, McGhee, Ewan, Timpson, Paul, Leach, Joshua, McGarry, Lynn, Shanks, Emma, Bailey, Peter, Chang, David, Oien, Karin, Karim, Saadia, Au, Amy, Steele, Colin, Carter, Christopher Ross, McKay, Colin, Anderson, Kurt, Evans, Thomas R Jeffry, Marais, Richard, Springer, Caroline, Biankin, Andrew, Erler, Janine T, Sansom, Owen J
Publicado 2015

Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer

por Dreyer, Stephan B., Pinese, Mark, Jamieson, Nigel B., Scarlett, Christopher J., Colvin, Emily K., Pajic, Marina, Johns, Amber L., Humphris, Jeremy L., Wu, Jianmin, Cowley, Mark J., Chou, Angela, Nagrial, Adnan M., Chantrill, Lorraine, Chin, Venessa T., Jones, Marc D., Moran-Jones, Kim, Carter, Christopher Ross, Dickson, Euan J., Samra, Jaswinder S., Merrett, Neil D., Gill, Anthony J., Kench, James G., Duthie, Fraser, Miller, David K., Cooke, Susanna, Aust, Daniela, Knösel, Thomas, Rümmele, Petra, Grützmann, Robert, Pilarsky, Christian, Nguyen, Nam Q., Musgrove, Elizabeth A., Bailey, Peter J., McKay, Colin J., Biankin, Andrew V., Chang, David K.
Publicado 2020